AbbVie Shorts Retreat to a Year Low as Barclays Lifts Target to $325

ABBV closed at $289.08 on Tuesday, up 5.4% on the week, with short interest at its lowest level in at least a year and a fresh analyst target raise landing the same morning.

Short interest has collapsed over the past six weeks. From a peak above 20 million shares short in mid-September, the position has been cut nearly in half to 15.4 million shares, now just 0.87% of the free float. That is a 25% reduction over the past month alone. The borrow market reflects just how little conviction remains on the short side: availability is effectively unlimited, with shares to lend running more than 100 times current short interest, and cost to borrow is a negligible 0.47%. This is not a setup with any squeeze dynamic. It is simply a stock where the short case has been abandoned at scale.

The Street has moved in the same direction. Barclays raised its target this morning to $325 from $300, maintaining an Overweight rating, making it the most prominent move in a string of upgrades that has run through October. Morgan Stanley lifted its target to $310, JPMorgan to $300, and Scotiabank to $320, all within the past two weeks. The consensus mean target is $283.50, which the stock has now traded through. UBS sits at $275 with a Neutral rating, the most visible holdout from the bullish chorus. The bull case rests on Skyrizi and Rinvoq absorbing the Humira decline and supporting double-digit EPS growth, along with a portfolio broadened by the Cerevel and ImmunoGen acquisitions. Bears point to Imbruvica TRx down 17% year-on-year, pricing pressure across the book, and a Q3 print that missed EPS by $0.10 after a $216 million IPR&D charge. The forward earnings yield has compressed to around 5.5%, with the P/E now at 18.3, up roughly 1.4 points over the past month as the stock has re-rated higher.

Among correlated peers, the week's move looks broadly in line. AMGN gained 6.3%, BIIB added 6.2%, and VRTX rose 6.1%. HALO was the outlier, up 13.5% on its own catalyst. ABBV's 5.4% is slightly below the peer median, which is notable given the stock has led large-cap biopharma on a year-to-date basis. The ORTEX short score has eased to 30.9, consistent with the low short interest, and the dividend score ranks in the 98th percentile of the universe, a floor that defensive allocators keep well in mind at this price level.

One signal worth noting from the alt data layer: Wikipedia traffic for AbbVie spiked to a z-score of 2.9 against its own 90-day history as of October 1, indicating a sharp uptick in retail attention around the time of the Q3 release. Separately, trial completion date slippage across the company's clinical pipeline registered a z-score of minus 2.1 as of late September, the largest negative reading in the available history. Neither dataset has been measured to lead AbbVie's reported financials, so neither is a read on the next print, but the trial slippage signal is worth tracking as the pipeline broadens.

The next fixed date on the calendar is the Q4 earnings release, with no confirmed date yet but the prior cadence pointing to late January. Between now and then, the question is whether the stock can hold above the $283.50 consensus target level it has already cleared, and whether any of the bears currently sitting on just 0.87% of the float find a reason to rebuild.